Matching cancer patients to treatment based on their levels of a key immune protein may allow doctors to select those who would benefit most from the combination of immunotherapy and chemotherapy, researchers report.

Six researchers at the ICR and The Royal Marsden have been named in a list of the world's most influential by the by science analytics company Clarivate.

An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests.